Pediatric Atopic Dermatitis: New Guidelines, New Treatments, New Questions
In this episode, host Jenn Dawson talks with Dr. Dawn Davis, Dr. Amy Paller, and Dr. Larry Eichenfield about the newly published pediatric atopic dermatitis guidelines and what they mean for clinicians, patients, and families. Together, they unpack the evidence behind prevention, comorbidities, and treatment recommendations, discuss how rapidly the therapeutic landscape is evolving, and highlight the biggest unanswered questions that remain in research. The conversation also explores the importance of patient advocacy, shared decision-making, and improving access to care as the field moves toward more personalized treatment.
Keywords: Guidelines, Atopic Dermatitis, Pediatricians, Primary Care, Research
Dr. Davis has no relevant disclosures or conflicts of interest.
Disclosures
Investigator: AbbVie, Biomendics, Dermavant, Eli Lilly, Incyte, Johnson & Johnson Innovative Medicine, Moonlake, Quoin, Regeneron, TheraClean, TWI, UCB.
Consultant for: Abeona, Almirall, Apogee, APR Applied Pharma Res, Arcutis, BioCryst, Boehringer-Ingelheim, Chiesi, Gedeon Richter, Johnson & Johnson Innovative Medicine, Kamari, Lilly, L’Oreal, MoonLake Immunotherapeutics, Novartis, Palvella, Pelthos, Pfizer, Quoin, Sanofi, and Takeda.
Data safety monitoring board for AbbVie, Abeona, Biocryst, and Galderma
Disclosures
Lawrence Eichenfield, MD has served as a consultant, advisor or investigator for AbbVie, Abeona, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol-Myers Squibb, Castle Biosciences, Chiesi, Corevitas, Dermavant, Formation Bio, Forte, Galderma, Incyte, Janssen, Kenvue, Kymera, Krystal, LEO, Lilly, Novartis, OrthoDerm, Pfizer, Regeneron, Sanofi Genzyme, Takeda, Target RWE, T-Rex, UCB and Verrica.
